Drug news
EU approves Gardasil to treat Anal Cancers- Sanofi Pasteur MSD
The European Commission has granted marketing authorisation for the use of Gardasil vaccine from Sanofi Pasteur MSD for the prevention of Anal precancerous lesions and Anal Cancers causally related to certain oncogenic human papillomavirus types in both males and females. Some 6,800 new cases of anal cancer are estimated to occur annually in Europe, among which about 75-80% are attributable to HPV types 16 and 18.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.